Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study

Luigi Gargiulo,Luciano Ibba,Andrea Cortese,Jessica Avagliano,Mario Valenti,Antonio Costanzo,Alessandra Narcisi

DOI: https://doi.org/10.1007/s13555-022-00882-z

2023-01-10

Dermatology and Therapy

Abstract:The treatment of severe atopic dermatitis (AD) includes cyclosporine and recently approved biologics and small molecules. Among these, upadacitinib is a selective inhibitor of Janus kinase 1, approved for the treatment of severe AD in adolescents/adults. Upadacitinib has shown efficacy and safety in several phase 3 clinical trials, but data on real-life patients are still lacking.

dermatology